Abstract
The fixed-dose combination canagliflozin/metformin is indicated in patients with type 2 diabetes as adjuvant therapy together with diet and exercise regimen, provided the disease cannot be controlled with monotherapy. Canagliflozin, a selective SGLT2 inhibitor, reduces the absorption of glucose and thus the renal glucose threshold.
Metformin may even exercise he mechanisms of action: reduction of the formation of glucose in the liver through the inhibition of gluconeogenesis and glycogen neogenesis, increased to insulin sensitivity in the muscles, improving peripheral absorption and utilisation of glucose, and delayed intestinal glucose absorption. The fixed-dose combination provides a welcome extension of our antidiabetic drugs portfolio based on its good efficacy and tolerance.